Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Revisão |
| Lingua: | inglese |
| Pubblicazione: |
2014
|
| Accesso online: | https://doi.org/10.1517/14728222.2014.960843 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|